Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/365—Lactones
  • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P23/00—Anaesthetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/02—Antidotes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to the modulation of ⁇ -secretase and cognitive enhancement.
• the invention further relates to compounds for treatment of conditions associated with amyloid processing such as Alzheimer's Disease and compositions for the treatment of such conditions.
• ADHD Attention Deficit Hyperactivity Disorder
• Other conditions include general dementias associated with other neurological diseases, aging, and treatment of conditions that can cause deleterious effects on mental capacity, such as cancer treatments, stroke/ischemia, and mental retardation.
• cognition enhancers or activators that have been developed are generally classified to include nootropics, vasodilators, metabolic enhancers, psychostimulants, cholinergic agents, biogenic amine drugs, and neuropeptides.
• Vasodilators and metabolic enhancers e.g. dihydroergotoxine
• cognition enhancers typically only metabolic drugs are employed for clinical use, as others are still in the investigation stage.
• piracetam activates the peripheral endocrine system, which is not appropriate for Alzheimer's disease due to the high concentration of steroids produced in patients while tacrine, a cholinergic agent, has a variety of side effects including vomiting, diarrhea, and hepatotoxicity.
• Alzheimer's Disease is typically associated with the formation of plaques through the accumulation of amyloid precursor protein. Attempts to illicit an immunological response through treatment against amyloid and plaque formation have been done in animal models, but have not been successfully extended to humans.
• cholinesterase inhibitors only produce some symptomatic improvement for a short time and in only a fraction of the Alzheimer's Disease patients with mid to moderate symptoms and are thus only a useful treatment for a small portion of the overall patient population. Even more critical is that present efforts at improving cognition do not result in treatment of the disease condition, but are merely ameliorative of the symptoms. Current treatments do not modify the disease progression. These treatments have also included the use of a "vaccine" to treat the symptoms of Alzheimer's Disease patients which, while theoretically plausible and effective in mice tests, have been shown to cause severe adverse reactions in humans. As a result, use of the cholinergic pathway for the treatment of cognitive impairment, particularly in Alzheimer's Disease, has proven to be inadequate.
• Alzheimer's disease is associated with extensive loss of specific neuronal subpopulations in the brain with memory loss being the most universal symptom. (Katzman, R. (1986) New England Journal of Medicine 314:964). Alzheimer's disease is well characterized with regard to neuropathological changes. However, abnormalities have been reported in peripheral tissue supporting the possibility that Alzheimer's disease is a systemic disorder with pathology of the central nervous system being the most prominent. (Connolly, G., Fibroblast models of neurological disorders: fluorescence measurement studies, Review, TiPS Vol. 19, 171-77 (1998)).
• Alzheimer's disease links to a genetic origin and chromosomes 1, 14, and 21 see St. George-Hyslop, P. H., et al., Science 235:885 (1987);Tanzi, Rudolph et al, The Gene Defects responsible for Familial Alzheimer's Disease, Review, Neurobiology of Disease 3, 159-168 (1996); Hardy, J., Molecular genetics of Alzheimer's disease, ActaNeurol Scand: Supplement 165: 13-17 (1996).
• K + and Ca 2+ channels have been demonstrated to play key roles in memory storage and recall.
• potassium channels have been found to change during memory storage.
• PKC was identified as one of the largest gene families of non-receptor serine- threonine protein kinases. Since the discovery of PKC in the early eighties by Nishizuka and coworkers (Kikkawa et al., J. Biol. Chem., 257, 13341 (1982), and its identification as a major receptor for phorbol esters (Ashendel et al., Cancer Res., 43, 4333 (1983)), a multitude of physiological signaling mechanisms have been ascribed to this enzyme. The intense interest in PKC stems from its unique ability to be activated in vitro by calcium and diacylglycerol (and its phorbol ester mimetics), an effector whose formation is coupled to phospholipid turnover by the action of growth and differentiation factors.
• the PKC gene family consists presently of 11 genes which are divided into four subgroups: 1) classical PKC ⁇ , ⁇ , ⁇ i ( ⁇ ⁇ and ⁇ 2 are alternatively spliced forms of the same gene) and ⁇ , 2) novel PKC ⁇ , e, ⁇ and ⁇ , 3) atypical PKC ⁇ , t ⁇ and i and 4) PKC ⁇ .
• PKC ⁇ resembles the novel PKC isoforms but differs by having a putative transmembrane domain (reviewed by Blohe et al., Cancer Metast. Rev., 13, 411 (1994); Hug et al., Biochem j., 291, 329 (1993); Kikkawa et al, Ann. Rev. Biochem.
• the , ⁇ ⁇ , ⁇ 2 , and ⁇ isoforms are Ca 2+ , phospholipid and diacylglycerol- dependent and represent the classical isoforms of PKC, whereas the other isoforms are activated by phospholipid and diacylglycerol but are not dependent on Ca 2+ . All isoforms encompass 5 variable (VI -V5) regions, and the a, ⁇ , ⁇ isoforms contain four (C1-C4) structural domains which are highly conserved.
• All isoforms except PKC ⁇ , ⁇ and ⁇ lack the C2 domain, and the ⁇ , ⁇ and isoforms also lack nine of two cysteine-rich zinc finger domains in Cl to which diacylglycerol binds.
• the Cl domain also contains the pseudosubstrate sequence which is highly conserved among all isoforms, and which serves an autoregulatory function by blocking the substrate-binding site to produce an inactive conformation of the enzyme (House et al., Science, 238, 1726 (1987)).
• PKC isoforms are thought to have highly specialized roles in signal transduction in response to physiological stimuli (Nishizuka, Cancer, 10, 1892 (1989)), as well as in neoplastic transformation and differentiation (Glazer, Protein Kinase C, J. F. Kuo, ed., Oxford U. Press (1994) at pages 171-198).
• PKC modulators see PCT/US97/08141, U.S. Patent Nos. 5,652,232; 6,043,270; 6,080,784; 5,891,906; 5,962,498; 5,955,501; 5,891,870 and 5,962,504.
• PKC has proven to be an exciting target for the modulation of APP processing. It is well established that PKC plays a role in APP processing. Phorbol esters for instance have been shown to significantly increase the relative amount of non-amyloidogenic soluble APP (sAPP) secreted through PKC activation. Activation of PKC by phorbol ester does not appear to result in a direct phosphorylation of the APP molecule, however. Irrespective of the precise site of action, phorbol-induced PKC activation results in an enhanced or favored ⁇ -secretase, non-amyloidogenic pathway.
• sAPP non-amyloidogenic soluble APP
• PKC activation is an attractive approach for influencing the production of non-deleterious sAPP and even producing beneficial sAPP and at the same time reduce the relative amount of A/3 peptides.
• Phorbol esters are not suitable compounds for eventual drug development because of their tumor promotion activity. (Ibarreta, et al., Benzolactam (BL) enhances sAPP secretion in fibroblasts and in PC12 cells, NeuroReport, Vol. 10, No. 5&6, pp 1035-40 (1999)).
• PKC isozymes play different, sometimes opposing, roles in biological processes, providing two directions for pharmacological exploitation.
• One is the design of specific (preferably, isozyme specific) inhibitors of PKC. This approach is complicated by the fact that the catalytic domain is not the domain primarily responsible for the isotype specificity of PKC.
• the other approach is to develop isozyme-selective, regulatory site-directed PKC activators. These may provide a way to override the effect of other signal transduction pathways with opposite biological effects. Alternatively, by inducing down-regulation of PKC after acute activation, PKC activators may cause long term antagonism. Bryostatin is currently in clinical trials as an anti-cancer agent.
• the bryostatins are known to bind to the regulatory domain of PKC and to activate the enzyme.
• Bryostatin is an example of isozyme-selective activators of PKC.
• Compounds in addition to bryostatins have been found to modulate PKC. (see for example WO 97/43268)
• the methods and compositions of the present invention fulfill these needs and will greatly improve the clinical treatment for Alzheimer's disease and other neurodegenerative diseases, as well as, provide for improved cognitive enhancement.
• the methods and compositions also provide treatment and/or enhancement of the cognitive state through the modulation of - secretase.
• the invention relates to compounds, compositions, and methods for the treatment of conditions associated with enhancement/improvement of cognitive ability.
• the present invention further relates to compounds, compositions and methods for the treatment of conditions associated with amyloid processing, such as Alzheimer's Disease, which provides for improved/enhanced cognitive ability in the subject treated.
• the compounds and compositions of the present invention are selected from macrocyclic lactones (i.e. bryostatin class and neristatin class).
• the invention in another aspect relates to macrocyclic lactone compounds, compositions and methods that modulate ⁇ -secretase activity.
• the bryostatin and neristatin class compounds are of particular interest.
• Another aspect of the invention relates to the bryostatin and neristatin class compounds, as a PKC activator, to alter conditions associated with amyloid processing in order to enhance the ⁇ -secretase pathway to generate soluble ⁇ -amyloid precursor protein (oAPP) so as to prevent /3-amyloid aggregation and improve/enhance cognitive ability.
• oAPP soluble ⁇ -amyloid precursor protein
• Such activation for example, can be employed in the treatment of Alzheimer's Disease.
• the invention in another aspect, relates to a method for treating plaque formation, such as that associated with Alzheimer's Disease, and improving/enhancing the cognitive state of the subject comprising administering to the subject an effective amount of a macrocyclic lactone to activate PKC.
• the PKC activator is of the bryostatin or neristatin class of compounds.
• the compound is bryostatin- 1.
• compositions for treating plaque formation and improving/enhancing cognitive ability comprising: (i) a macrocyclic lactone in an amount effective to elevate soluble jS-amyloid, generate soluble oAPP and prevent /3-amyloid aggregation; and (u) a pharmaceutically effective carrier.
• a macrocyclic lactone is preferably selected from the bryostatin or neristatin class compounds, particularly bryostatin- 1.
• the activation of PKC isoenzymes results in improved cognitive abilities, hi one embodiment the improved cognitive ability is memory. In another embodiment the improved cognitive ability is learning. In another embodiment the improved cognitive ability is attention.
• PKC's isoenzymes are activated by a macrocyclic lactone (i.e. bryostatin class and neristatin class). In particular, bryostatin-1 through 18 and neristatin is used to activate the PKC isoenzyme. In a preferred embodiment bryostatin- 1 is used.
• the invention comprises a composition of a PKC isoenzyme activator administered in an amount effective to improve cognitive abilities.
• the PKC isoenzyme activator is selected from macrocyclic lactones (i.e. bryostatin class and neristatin class).
• the amount of PKC activator administered is in an amount effective to increase the production of sAPP.
• the amount of composition administered does not cause myalgia.
• the PKC isoenzymes are activated in subjects, which are suffering or have suffered from neurological diseases, strokes or hypoxia. h a more preferred embodiment the PKC isoenzyme is activated in Alzheimer's Disease subjects or models.
• the PKC activation results in the modulation of amyloid precursor protein metabolism. Further the modulation by the PKC activation results in an increase in the alpha secretase pathway. The alpha secretase pathway results in non-toxic, non-amyloidogenic fragments related to cognitive impairment. As a result the cognitive condition of the subject improves.
• the PKC activation reduces the amyloidogenic and toxic fragments Abeta 40 and Ab42.
• Another embodiment of the invention is a method of improving cognitive ability through the activation of PKC isoenzymes.
• the PKC activation occurs in "no ⁇ nal" subjects, hi another embodiment of the invention the PKC activation occurs in subjects suffering from a disease, deteriorating cognitive faculties, or malfunctioning cognition.
• the method is a method for treating Alzheimer's Disease.
• the modulation of PKC is through the use of a non-tumor promoting agent resulting in improved cognitive abilities, hi a preferred embodiment the PKC activator is selected from bryostatin- 1 through bryostatin- 18 and neristatin. In a more preferred embodiment bryostatin- 1 is used, h another embodiment bryostatin- 1 is used in combination with a non-bryostatin class compound to improve cognitive ability and reduce side effects.
• the modulation of PKC through macrocyclic lactones i.e. bryostatin class and neristatin class
• the in vitro use may include for example, the testing of fibroblast cells, blood cells, or the monitoring of ion channel conductance in cellular models.
• the compounds and compositions are administered through oral and/or injectable forms including intravenously and intraventricularly.
• the present invention therefore provides a method of treating impaired memory or a learning disorder in a subject, the method comprising administering thereto a therapeutically effective amount of one of the present compounds.
• the present compounds can thus be used in the therapeutic treatment of clinical conditions in which memory defects or impaired learning occur. In this way memory and learning can be improved. The condition of the subject can thereby be improved.
• the compositions and methods have utility in treating clinical conditions and disorders in which impaired memory or a learning disorder occurs, either as a central feature or as an associated symptom. Examples of such conditions which the present compounds can be used to treat include Alzheimer's disease, multi-infarct dementia and the Lewy-body variant of Alzheimer's disease with or without association with Parkinson's disease; Creutzfeld- Jakob disease and Korsakow's disorder.
• compositions and methods can also be used to treat impaired memory or learning which is age-associated, is consequent upon electro-convulsive therapy or which is the result of brain damage caused, for example, by stroke, an anesthetic accident, head trauma, hj ⁇ oglycemia, carbon monoxide poisoning, lithium intoxication or a vitamin deficiency.
• the compounds have the added advantage of being non-tumor promoting and already being involved in phase II clinical trials.
• the invention relates to a pharmaceutical composition for enhancing cognition, preventing and/or treating cognition disorders. More particularly, it relates to the pharmaceutical composition comprising macrocyclic lactones (i.e. bryostatin class and neristatin class) and their derivatives as the active ingredient for enhancing cognition, preventing and/or treating cognition disorders.
• macrocyclic lactones i.e. bryostatin class and neristatin class
• the pharmaceutical composition comprises macrocyclic lactones, particularly the bryostatin and neristatin class, or a pharmaceutically acceptable salt or derivative thereof, and a pharmaceutically acceptable carrier or excipient.
• the pharmaceutical composition according to the invention is useful in the enhancement of cognition, prophylaxis and/or treatment of cognition disorders, wherein cognition disorders include, but are not limited to, disorders of learning acquisition, memory consolidation, and retrieval, as described herein.
• the invention concerns a method for the treatment of amyloidosis associated with neurological diseases, including Alzheimer's disease by administering to a patient an effective amount of at least one agent that modulates or affects the phosphorylation of proteins in mammalian cells.
• the invention also provides a method for treating Alzheimer's disease comprising administering to a patient an effective amount of a macrocyclic lactone (i.e. bryostatin class and neristatin class).
• the bryostatin or neristatin class compounds may be used in the above methods in combination with different phorbol esters to prevent or reduce tumorogenetic response in the subj ect.
• Fig. 1 illustrates the effect of different PKC inhibitors on sAPP ⁇ secretion with
• Fig. 2 illustrates the effect of different concentrations of Bryostatin- 1 on the PKC ⁇ isozyme.
• Fig. 3 illustrates the effect of different concentrations of Bryostatin- 1 on sAPP ⁇ secretion.
• Fig. 4 illustrates the amount of time required for treated rats verse controls to learn a water maze.
• Fig. 5(a) illustrates the amount of time control rats spent swimming in the different quadrants.
• Fig. 5(b) illustrates the amount of time treated rats spent swimming in the different quadrants.
• Fig. 5(c) illustrates the different between the amount of time the treated rats spent in target quadrant compared to control rats.
• Fig. 6 illustrates sAPP ⁇ secretion in human fibroblast cells following administration of bryostatin 0.1 nM for both controls and AD cells.
• Fig. 7 illustrates an immunoblot for sAPP following administration of bryostatin in AD cells.
• Memory loss and impaired learning ability are features of a range of clinical conditions. For instance, loss of memory is the most common symptom of dementia states including Alzheimer's disease. Memory defects also occur with other kinds of dementia such as multi-infarct dementia (MID), a senile dementia caused by cerebrovascular deficiency, and the Lewy-body variant of Alzheimer's disease with or without association with Parkinson's disease, or Creutzfeld-Jakob disease. Loss of memory is a common feature of brain-damaged patients.
• MID multi-infarct dementia
• senile dementia caused by cerebrovascular deficiency
• Lewy-body variant of Alzheimer's disease with or without association with Parkinson's disease
• Creutzfeld-Jakob disease Creutzfeld-Jakob disease. Loss of memory is a common feature of brain-damaged patients.
• Brain damage may occur, for example, after a classical stroke or as a result of an anesthetic accident, head trauma, hypoglycemia, carbon monoxide poisoning, lithium intoxication, vitamin (Bl, thiamine and B12) deficiency, or excessive alcohol use or Korsakow's disorder.
• Memory impairment may furthermore be age-associated; the ability to recall information such as names, places and words seems to decrease with increasing age.
• Transient memory loss may also occur in patients, suffering from a major depressive disorder, after electro- convulsive therapy (ECT).
• ECT electro- convulsive therapy
• Alzheimer's disease is in fact the most important clinical entity responsible for progressive dementia in ageing populations, whereas hypoxia/stroke is responsible for significant memory defects not related to neurological disorders.
• Alzheimer's disease is characterized by progressive memory impairments, loss of language and visuospatial skills and behavior deficits (McKhann et al, 1986, Neurology, 34:939-944).
• the cognitive impairment of individuals with Alzheimer's disease is the result of degeneration of neuronal cells located in the cerebral cortex, hippocampus, basal forebrain and other brain regions.
• Histologic analyses of Alzheimer's disease brains obtained at autopsy demonstrated the presence of neurofibrillary tangles (NFT) in perikarya and axons of degenerating neurons, extracellular neuritic (senile) plaques, and amyloid plaques inside and around some blood vessels of affected brain regions.
• NFT neurofibrillary tangles
• Neurofibrillary tangles are abnormal filamentous structures containing fibers (about 10 mn in diameter) that are paired in a helical fashion, therefore also called paired helical filaments. Neuritic plaques are located at degenerating nerve terminals (both axonal and dendritic), and contain a core compound of amyloid protein fibers. In summary, Alzheimer's disease is characterized by certain neuropathological features including intracellular neurofibrillary tangles, primarily composed of cytoskeletal proteins, and extracellular parenchymal and cerebrovascular amyloid.
• AD Alzheimer's disease
• AD Alzheimer's disease
• APP amyloid precursor protein
• a central feature of the pathology of Alzheimer's disease is the deposition of amyloid protein within plaques.
• the processing of the amyloid precursor protein (APP) determines the production of fragments that later aggregate forming the amyloid deposits characteristic of Alzheimer's disease (AD), known as senile or AD plaques.
• AD Alzheimer's disease
• APP processing pathways Three alternative APP processing pathways have been identified.
• the previously termed "normal" processing involves the participation of an enzyme that cleaves APP within the A5 sequence at residue Lysl6 (or between Lysl6 and Leul7; APP770 nomenclature), resulting in non-amyloidogenic fragments: a large N-terminus ectodomain and a small 9 Da membrane bound fragment.
• This enzyme yet to be fully identified, is known as ⁇ -secretase.
• Two additional secretases participate in APP processing.
• One alternative pathway involves the cleavage of APP outside the A/3 domain, between Met671 and Asp672 (by /3-secretase) and the participation of the endosomal-lysomal system.
• cultured cells transfected with this mutation or the APP 717 mutation secrete larger amounts of A/3. More recently, carriers of other APP mutations and PS1 and PS2 mutations have been shown to secrete elevated amounts of a particular form, long (42-43 amino acids) A/3.
• the PKC isoenzymes provides a critical, specific and rate limiting molecular target through which a unique correlation of biochemical, biophysical, and behavioral efficacy can be demonstrated and applied to subjects to improve cognitive ability.
• PKC protein kinase
• Alterations in PKC, as well alterations in calcium regulation and potassium (K ) channels are included among alterations in fibroblasts in Alzheimer's disease (AD) patients.
• PKC activation has been shown to restore normal K + channel function, as measured by TEA-induced [Ca + ] elevations.
• Further patch-clamp data substantiates the effect of PKC activators on restoration of 113pS K + channel activity.
• PKC activator-based restoration of K channels has been established as an approach to the investigation of AD pathophysiology, and provides a useful model for AD therapeutics. (See pending applications 09/652,656 herein incorporated in its entirety.)
• AD Alzheimer's disease
• animal neuronal cells peripheral tissues from Alzheimer's disease (AD) patients and animal neuronal cells permitted the identification of a number of cellular/molecular alterations reflecting comparable processes in the AD brain and thus, of pathophysiological relevance (Baker et al., 1988; Scott, 1993; Huang, 1994; Scheuner et al., 1996; Etcheberrigaray & Alkon, 1997; Gasparini et al., 1997). Alteration of potassium channel function has been identified in fibroblasts (Etcheberrigaray et al., 1993) and in blood cells (Bondy et al., 1996) obtained from AD patients.
• fibroblasts with known dysfunctional K + channels treated with PKC activators restore chamiel activity as monitored by the presence/absence of TEA-induced calcium elevations.
• assays based on tetraethylammonium chloride (TEA)-induced [Ca 2+ ] elevation have been used to show functional 113pS K + channels that are susceptible to TEA blockade (Etcheberrigaray et al., 1993, 1994; Hirashima et al., 1996).
• TEA tetraethylammonium chloride
• TEA-induced [Ca 2+ ] elevations and K + channel activity observed in fibroblasts from control individuals are virtually absent in fibroblasts from AD patients (Etcheberrigaray et al., 1993; Hirashima et al., 1996).
• PKC activators can restore the responsiveness of AD fibroblast cell lines to the TEA challenge.
• immunoblot evidence from these studies demonstrate that this restoration is related to a preferential participation of the isoform.
• the present inventors have also observed that activation of protein kinase C favors the ⁇ -secretase processing of the Alzheimer's disease (AD) amyloid precursor protein (APP), resulting in the generation of non-amyloidogenic soluble APP (sAPP). Consequently, the relative secretion of amyloidogenic A 1 - 0 and A 1- 2( ) is reduced. This is particularly relevant since fibroblasts and other cells expressing APP and presenilin AD mutations secrete increased amounts of total A/3 and/or increased ratios of Interestingly, PKC defects have been found in AD brain ( and ⁇ isoforms) and in fibroblasts (c-isoform) from AD patients.
• Synapses are considered a critical site at final targets through which memory-related events realize their functional expression, whether the events involve changed gene expression and protein translation, altered kinase activities, or modified signaling cascades.
• a few proteins have been implicated in associative memory including Ca 2+ /calmodulin II kinases, protein kinase C, calexcitin, a 22-kDa learning-associated Ca 2+ binding protein, and type II ryanodine receptors.
• the modulation of PKC through the administration of macrocyclic lactones provides a mechanism to effect synaptic modification.
• the area of memory and learning impairment is rich in animal models that are able to demonstrate different features of memory and learning processes. (See, for example, Hollister, L. E., 1990, Pharmacopsychiat, 23, (Suppl II) 33-36).
• the available animal models of memory loss and impaired learning involve measuring the P T/US03/07101
• abnormal is meant to include individuals who have not been diagnosis with or currently display diminished or otherwise impaired cognitive function.
• the different cognitive abilities may be tested and evaluated through known means well established in the art, including but not limited to tests from basic motor- spatial skills to more complex memory recall testing.
• tests used for cognitive ability for non-primates include the Morris Water Maze, Radial Maze, T Maze, Eye Blink Conditioning, Delayed Recall, and Cued Recall while for primate subjects test may include Eye Blink, Delayed Recall, Cued Recall, Face Recognition, Minimental, and ADAS-Cog. Many of these tests are typically used in the mental state assessment for patients suffering from AD. Similarly, the evaluation for animal models for similar purposes with well describe in the literature.
• bryostatin class and neristatin class macrocyclic lactones
• bryostatin-1 has been shown to activate PKC and proven to be devoid of tumor promotion activity.
• Bryostatin- 1 as a PKC activator, is also particularly useful since the dose response curve of bryostatin- 1 is biphasic.
• bryostatin- 1 demonstrates differential regulation of PKC isozymes, including PKC ⁇ , PKC ⁇ , and PKCe.
• Bryostatin-1 has undergone toxicity and safety studies in animals and humans and is actively being investigated as an anti-cancer agent.
• Bryostatin- l has determined that the main adverse reaction in humans is myalgia, limiting the maximum dose to 40 mg/m .
• the present invention has utilized concentrations of 0.1 nM of bryostatin- 1 to cause a dramatic increase of sAPP secretion.
• Bryostatin- 1 has been compared to a vehicle alone and to another PKC activator, benzolactam (BL), used at a concentration 10,000 times higher. Also bryostatin used at 0.01 nM still proved effective to increase sAPP secretion. (See Figure 1).
• PKC translocation shows that a measure of activation is maximal at 30 min, followed by a partial decline, which remains higher than basal translocation levels up to six hours, (see Figures 2,3, & 7).
• the use of the PKC inhibitor staurosporin completely prevents the effect of bryostatin on sAPP secretion.
• the data further demonstrates that PKC activation mediates the effect of the bryostatin on sAPP secretion, (see Figures 1-3)
• Macrocyclic lactones, and particularly bryostatin- 1 is described in U.S. Patent 4,560,774.
• Macrocyclic lactones and their derivatives are described elsewhere in the art for instance in U.S. Patent 6,187,568, U.S. Patent 6,043,270, U.S. Patent 5,393,897, U.S. Patent 5, 072,004, U.S. Patent 5,196,447, U.S. Patent 4,833,257, and U.S. Patent 4,611,066.
• the above patents describe various compounds and various uses for macrocyclic lactones including their use as an anti-inflammatory or anti-tumor agent.
• bryostatin class compounds can be found in: Differential Regulation of Protein Kinase C Isozymes by Bryostatin 1 and Phorbol 12-Myristate 13- Acetate in NIH 3T3 Fibroblasts, Szallasi et al., Journal of Biological Chemistry, Vol. 269, No. 3, pp.
• Bryostatin 1 an Activator of Protein Kinase C, Zhang et al., Caner Research 56, 802-808 (1996); Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin, Hennings et al., Carcinogenesis vol. 8, no. 9, pp 1343-46 (1987); Phase II Trial of Bryostatin 1 in Patients with Relapse Low-Grade Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Varterasian et al., Clinical Cancer Research, Vol. 6, pp. 825-28 (2000); and Review Article: Chemistry and Clinical Biology of the Bryostatins, Mutter et al., Bioorganic & Medicinal Chemistry 8, pp. 1841-1860 (2000).
• Macrocyclic lactones including the bryostatin class, represent known compounds, originally derived from Bugula neritina L. While multiple uses for macrocyclic lactones, particularly the bryostatin class are known, the relationship between macrocyclic lactones and cognition enhancement was previously unknown.
• the examples of the compounds that may be used in the present invention include macrocyclic lactones (i.e. bryostatin class and neristatin class compounds). While specific embodiments of these compounds are described in the examples and detailed description, it should be understood that the compounds disclosed in the references and derivatives thereof could also be used for the present compositions and methods.
• macrocyclic lactone compounds and their derivatives are amenable to combinatorial synthetic techniques and thus libraries of the compounds can be generated to optimize pharmacological parameters, including, but not limited to efficacy and safety of the compositions. Additionally, these libraries can be assayed to determine those members that preferably modulate ⁇ -secretase and/or PKC.
• Combinatorial libraries high throughput screening of natural products and fermentation broths has resulted in the discovery of several new drugs.
• generation and screening of chemical diversity is being utilized extensively as a major technique for the discovery of lead compounds, and this is certainly a major fundamental advance in the area of drug discovery.
• combinatorial techniques provide for a valuable tool for the optimization of desired biological activity.
• the subject reactions readily lend themselves to the creation of combinatorial libraries of compounds for the screening of pharmaceutical, or other biological or medically-related activity or material-related qualities.
• a combinatorial library for the purposes of the present invention is a mixture of chemically related compounds, which may be screened together for a desired property; said libraries may be in solution or covalently linked to a solid support.
• the preparation of many related compounds in a single reaction greatly reduces and simplifies the number of screening processes that need to be carried out. Screening for the appropriate biological property may be done by conventional methods.
• the present invention also provides methods for determining the ability of one or more inventive compounds to bind to effectively modulate ⁇ -secretase and/or PKC.
• the present compounds can be administered by a variety of routes and in a variety of dosage forms including those for oral, rectal, parenteral (such as subcutaneous, intramuscular and intravenous), epidural, intrathecal, intra-articular, topical and buccal administration.
• the dose range for adult human beings will depend on a number of factors including the age, weight and condition of the patient and the administration route.
• fine powders or granules containing diluting, dispersing and/or surface-active agents may be presented in a draught, in water or a syrup, in capsules or sachets in the dry state, in a non-aqueous suspension wherein suspending agents may be included, or in a suspension in water or a syrup.
• flavouring, preserving, suspending, thickening or emulsifying agents can be included.
• Other compounds which may be included by admixture are, for example, medically inert ingredients, e.g. solid and liquid diluent, such as lactose, dextrose, saccharose, cellulose, starch or calcium phosphate for tablets or capsules, olive oil or ethyl oleate for soft capsules and water or vegetable oil for suspensions or emulsions; lubricating agents such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; gelling agents such as colloidal clays; thickening agents such as gum tragacanth or sodium algmate, binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinylpyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuff; sweeteners; wetting agents such as lecithin, polysorbates
• Liquid dispersions for oral administration may be syrups, emulsions or suspensions.
• the syrups may contain as carrier, for example, saccharose or saccharose with glycerol and/or mannitol and/or sorbitol. h particular a syrup for diabetic patients can contain as carriers only products, for example sorbitol, which do not metabolize to glucose or which metabolize only a very small amount to glucose.
• the suspensions and the emulsions may contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
• Suspensions or solutions for intramuscular injection may contain, together with the active compound, a pharmaceutically acceptable carrier such as sterile water, olive 03 07101
• Solutions for intravenous injection or infusion may contain a carrier, for example, sterile water that is generally Water for Injection. Preferably, however, they may take the form of a sterile, aqueous, isotonic saline solution. Alternatively, the present compounds may be encapsulated within liposomes. The present compounds may also utilize other known active agent delivery systems.
• the present compounds may also be administered in pure form unassociated with other additives, in which case a capsule, sachet or tablet is the preferred dosage form.
• Tablets and other forms of presentation provided in discrete units conveniently contain a daily dose, or an appropriate fraction thereof, of one of the present compounds.
• units may contain from 5 mg to 500 mg, but more usually from 10 mg to 250 mg, of one of the present compounds.
• compositions of the invention can be demonstrated using standard pharmacological models that are known in the art.
• inventive compositions can be incorporated or encapsulated in a suitable polymer matrix or membrane for site- specific delivery, or can be functionalized with specific targeting agents capable of effecting site specific delivery. These techniques, as well as other drug delivery techniques are well known in the art.
• Immunoblot experiments were conducted using well-established procedures (Dunbar, 1994). Cells were grown to confluency (-90%) in 6 cm Petri dishes. Levels of isozyme in response to treatment with 0.1 nM bryostatin- 1 for 5, 30, 60, and 120 minutes was quantified using procedures slightly modified from that established by Racchi et al., (1994). Fibroblasts were washed twice with ice-cold PBS, scraped in PBS, and collected by low-speed centrifugation.
• the pellets were re-suspended in the following homogenization buffer: 20 rnM Tris-HCl, pH 7.5, 2 mM EDTA, 2mM EGTA, 5 mM DTT, 0.32 M sucrose, and protease inhibitor cocktail (Sigma). Homogenates were obtained by sonication, and centrifuged at ⁇ 12,000g for 20 minutes, and the supematants were used as the cytosolic fraction. The pellets were homogenized in the same buffer containing 1.0% Triton X-100, incubated in ice for 45 minutes, and centrifuged at ⁇ 12,000g for 20 minutes. The supernatant from this batch was used as the membranous fraction.
• the concentration of secreted APP was measured using conventional immunoblotting techniques, with minor modifications the protocol. Precipitated protein extracts from each dish/treatment were loaded to freshly prepared 10% acrylamide Tris ⁇ Cl minigels and separated by SDPAGE. The volume of sample loaded was corrected for total cell protein per dish. Proteins were then electrophoretically transferred to PVDF membranes. Membranes were saturated with 5% non-fat dry milk to block non-specific binding. Blocked membranes were incubated overnight at 4 °C with the commercially available antibody 6E10 (1:500), which recognizes sAPP-alpha in the conditioned medium (SENETEK).
• Bryostatin- 1 elicits a powerful response, demonstrating the activation of PKC, It should be noted the activation of PKC is easily detectable 30 minutes after delivery, following a dose of only 0.1 nM of bryostatin- 1.
• AD cell lines exhibit both defective PKC and impaired sAPP secretion (Bergamaschi et al., 1995; Govoni et al., 1996).
• ⁇ - amyloid has been shown to induce an AD-like K + channel defect in fibroblasts (Etcheberrigaray et al., 1994) and to block K + currents in cultured neurons (Good et al., 1996). Therefore, we suggest a mechanistic link such that an isozyme-specific PKC defect may lead to abnormal APP processing that, among other possible deleterious effects, alters K + channel function.
• Recent preliminary data also suggest that, perhaps in a vicious cyclical manner, /3-amyloid in turn causes reductions of PKC (Favit et al., 1997).
• bryostatin- 1 PKC activators, particularly bryostatin- 1
• phase II studies for AD treatment/cognitive enhancement could be expedited.
• bryostatin-l's lipophilic nature provides increased blood brain barrier transport.
• the present invention would allow for intravenous, oral, intraventricullar, and other known methods of administration.

Landscapes

• Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Nutrition Science (AREA)
• Psychology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Physiology (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Emergency Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Anesthesiology (AREA)
• Toxicology (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (16)

Applications Claiming Priority (4)

Related Child Applications (2)

Publications (3)

Family

ID=27807411

Family Applications (1)

Country Status (7)

Cited By (10)

Families Citing this family (23)

Family Cites Families (72)

• 2002
  • 2002-06-13 US US10/167,491 patent/US6825229B2/en not_active Expired - Lifetime
• 2003
  • 2003-03-07 CA CA002477973A patent/CA2477973A1/en not_active Abandoned
  • 2003-03-07 WO PCT/US2003/007101 patent/WO2003075850A2/en not_active Ceased
  • 2003-03-07 JP JP2003574126A patent/JP2005527512A/ja not_active Withdrawn
  • 2003-03-07 EP EP03716386.2A patent/EP1490050B1/en not_active Expired - Lifetime
  • 2003-03-07 EP EP10000734.3A patent/EP2172246B1/en not_active Expired - Lifetime
  • 2003-03-07 AU AU2003220096A patent/AU2003220096A1/en not_active Abandoned
  • 2003-03-07 ES ES10000734.3T patent/ES2639578T3/es not_active Expired - Lifetime
• 2004
  • 2004-09-03 US US10/933,536 patent/US20050037984A1/en not_active Abandoned
• 2013
  • 2013-03-27 US US13/851,161 patent/US9539235B2/en not_active Expired - Fee Related
• 2015
  • 2015-11-02 US US14/929,731 patent/US9446020B2/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events